---
schema_version: "secwatch.filing_event.v1"
accession: "0001689548-22-000124"
form_type: "8-K"
ticker: "PRAX"
cik: "0001689548"
company_name: "Praxis Precision Medicines, Inc."
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T01:31:07.443376+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Praxis Q3 2022 net loss $43.9M; cash $123.7M; PRAX-944 top-line results expected 1Q23

## Summary
- Net loss $43.9M vs $44.7M YoY; R&D expenses $30.4M down from $33.1M.
- Cash and investments $123.7M, down from $275.9M at year-end 2021; runway into 1Q24.
- PRAX-944 Phase 2b Essential1 top-line results for essential tremor expected 1Q23; screening to complete mid-Nov 2022.
- PRAX-222 EMBRAVE study for SCN2A-DEE to initiate in 4Q22; initial dose cohort results expected 2023.
- PRAX-114 Phase 2 Acapella study in MDD not statistically significant; no further development planned.

## SEC filing metadata
- accession: 0001689548-22-000124
- form_type: 8-K
- ticker: PRAX
- cik: 0001689548
- company_name: Praxis Precision Medicines, Inc.
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689548/000168954822000124/0001689548-22-000124-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689548/000168954822000124/prax-20221109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001689548-22-000124
- JSON: https://secwatch.observer/filing/0001689548-22-000124.json
- Plain text: https://secwatch.observer/filing/0001689548-22-000124.txt

## Key facts
- Earnings Releases
  Praxis Precision Medicines, Inc. reported financial results for the third quarter of 2022.
  - Period: the third quarter of 2022
  - Result: reported results
  source text: On November 9, 2022, Praxis Precision Medicines, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1689548/000168954822000124/0001689548-22-000124-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.